Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Multiple Myeloma: early-phase trial registry
23 of 68 indexed Refractory Multiple Myeloma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #203 of 28,707 conditions by registered trial count.
68 US clinical trials · 23 currently recruiting · #203 of 28,707 conditions by registered trial count
Refractory Multiple Myeloma: 68 US clinical trials tracked, 23 recruiting.
Refractory Multiple Myeloma is the subject of 68 registered US clinical trials on ClinicalTrials.gov, 23 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 63 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 35 of these trials.
Enrollment posture brief
Registry condition refractory-multiple-myeloma
OPEN 23 | RECR 34% | LATE 2 | EARLY 63 | RANK #203 | SPON 35
Volume-matched condition peers
Nearest open-share peer: Breast Cancer (34% recruiting · 1,251 trials)
Refractory Multiple Myeloma lists 23 open slots (34% of 68 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Multiple Myeloma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Multiple Myeloma is recruiting below its size-band peers.
23 of 68 indexed trials (33.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Refractory Multiple Myeloma research.
National Cancer Institute (NCI) accounts for 35 of 68 trials (51.5%). 24 distinct sponsors appear on at least one study for this condition label.
-
Most Refractory Multiple Myeloma trials plan to enrol fewer than 100 people.
Median target enrolment is 35 among the 68 trials that report a genuine target (sentinel values excluded). 62 of those (91.2%) plan for fewer than 100 participants.
-
Refractory Multiple Myeloma research is mostly interventional.
68 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
68 total, page 2 of 2
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
National Cancer Institute (NCI)
NCT06360575
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
National Cancer Institute (NCI)
NCT06385483
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
National Cancer Institute (NCI)
NCT06303167
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT05431608
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
National Cancer Institute (NCI)
NCT06390826
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
NCT04302324
Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma
Thomas Martin, MD
NCT05577000
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
National Cancer Institute (NCI)
NCT04439266
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
National Cancer Institute (NCI)
NCT04439253
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
National Cancer Institute (NCI)
NCT04439357
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
Elvira Umyarova
NCT06203912
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
Fred Hutchinson Cancer Center
NCT00217438
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00028821
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT00303797
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
Fred Hutchinson Cancer Center
NCT00006244
Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Fred Hutchinson Cancer Center
NCT00054353
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Alliance Foundation Trials
NCT03702725
Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment
National Cancer Institute (NCI)
NCT03770260
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 22 |
| Phase 2 | 41 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Multiple Myeloma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Multiple Myeloma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Multiple Myeloma page
68 registered trials, 23 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 23 Refractory Multiple Myeloma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Refractory Multiple Myeloma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Multiple Myeloma condition card totals 68 registered trials; most-linked intervention Biospecimen Collection; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.